Talis Biomedical Corporation
230 Constitution Dr.
Menlo Park
CA
94025
United States
Tel: 650-433-3000
Website: https://talis.bio/
Email: info@talisbio.com
40 articles about Talis Biomedical Corporation
-
Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
11/14/2023
Talis Biomedical Corporation announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value.
-
Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update
8/10/2023
Talis Biomedical Corporation, a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, reported financial results for the second quarter ended June 30, 2023, and provided a business update.
-
Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)
8/2/2023
Talis Biomedical Corporation today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023.
-
New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu
7/27/2023
Talis Biomedical Corporation (Nasdaq: TLIS) today announced new data supporting the development of its planned CT/NG/TV and vaginal infection panels.
-
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
7/24/2023
Talis Biomedical Corporation today announced that it received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated July 20, 2023, that the Company has regained compliance with the minimum bid price requirement of at least $1.00 per share.
-
Talis Biomedical Announces 1-for-15 Reverse Stock Split
7/5/2023
Talis Biomedical Corporation today announced that it will effect a 1-for-15 reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share (the “Reverse Stock Split”), effective at 5:00 p.m. Eastern time on July 5, 2023 (the “Effective Time”).
-
Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director
5/23/2023
Talis Biomedical Corporation, a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, announced Heiner Dreismann has joined its board of directors, effective immediately.
-
Talis Biomedical Announces Business Update and First Quarter 2023 Financial Results
5/11/2023
Talis Biomedical Corporation announced a business update and reported financial results for the first quarter ended March 31, 2023.
-
Talis Biomedical to Provide Business Update and Financial Results on May 11, 2023
5/4/2023
Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will provide a business update and financial results on Thursday, May 11, 2023, after market close.
-
Talis Announces Fourth Quarter and Full Year 2022 Financial Results
3/22/2023
Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the fourth quarter and full year ended December 31, 2022.
-
Talis Biomedical Reports Third Quarter 2022 Financial Results
11/3/2022
Talis Biomedical Corporation, a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, reported financial results for the third quarter ended September 30, 2022.
-
Between top-notch academic institutions, solid venture capital funding, expanding lab space and governmental support, Chicago is emerging as a true hotbed for biotech growth.
-
As a leading biotech hub, the second city still ranks far below many other U.S. locations. That is starting to change, however, as new companies move into the heart of the BioMidwest region.
-
Biogen expects to lay off a potential 1,000 staffers in an effort to cut about $1 billion in costs, according to The Boston Globe, while 10x Genomics and Talis Biomedical also cut staff.
-
Talis Biomedical Provides Business Update and Reports Second Quarter Financial Results
8/2/2022
Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today provided a business update and reported financial results for the second quarter ended June 30, 2022.
-
Talis Biomedical Announces First Quarter 2022 Financial Results
5/10/2022
Talis Biomedical Corporation reported financial results for the first quarter ended March 31, 2022.
-
Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022
4/26/2022
Talis Biomedical Corporation announced that it will report first quarter financial results on Tuesday, May 10, 2022, after market close.
-
Talis Biomedical Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
3/15/2022
Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Talis Biomedical to Announce Fourth Quarter and Full Year Financial Results on March 15, 2022
3/1/2022
Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report fourth quarter and full year 2021 financial and operational results on Tuesday, March 15, 2022, after market close.
-
Talis Biomedical Announces Leadership Transition - Dec 08, 2021
12/8/2021
Talis Biomedical Corporation, a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, announced that Rob Kelley, the Company’s current Chief Commercial Officer, has been promoted to Chief Executive Officer and Director, effective immediately.